MindMed completes Phase 2b trial enrollment for MM-120 in GAD treatment
MindMed Inc., a clinical-stage biopharmaceutical company, has announced the completion of enrollment and dosing in its Phase 2b study, MMED008, which focuses on the treatment of Generalized Anxiety Disorder (GAD) with MM-120 (lysergide D-tartrate). The study enrolled 198 participants, reaching a significant milestone in the company’s efforts to transform GAD treatment. MindMed’s MMED008 study is […]